$CRMD

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex

CorMedix Therapeutics (CRMD) reported $355M in cash reserves as of Q3 2026 and reaffirmed its 2026 revenue guidance of $325M-$345M. CMS set an $8.32 Add-on payment per DefenCath dialysis session for Q1 2027, within CorMedix's guided range. The company expects the Add-on to decline in Q2 2027 but increase in later quarters, with an average rate exceeding 2x the current $2.37. CorMedix will discuss its Q3 financial results on November 12, 2026.

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CORMEDIX ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES Parsippany, NJ – October 19, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Admini

CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO® to prevent fungal infections in stem-cell transplant patients, granting Priority Review with a Q1 2027 target action date. The application is based on the Phase III ReSPECT study, which showed positive results in April. If approved, CorMedix plans to begin promotional efforts in H2 2027.

RBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.

CorMedix (CRMD) was upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, which often impacts stock prices. The Zacks rating system tracks consensus EPS estimates, and upgrades typically signal a positive earnings outlook, potentially boosting the stock price.

CorMedix (CRMD) reported Q2 2026 revenue of $101.9M and adjusted EBITDA of $58.7M. The company signed a commercial supply agreement for DefenCath with a large dialysis organization, covering all top U.S. providers. Full-year revenue guidance was reaffirmed at $325M-$345M, while adjusted EBITDA guidance was raised to $125M-$140M. CorMedix anticipates submitting an sNDA for REZZAYO in Q3 2026, with potential FDA action in H1 2027. The company plans to invest in commercial infrastructure for a pote

CorMedix reported Q2 2026 progress on DefenCath and its REZZAYO pipeline. The company secured a multi-year supply agreement covering all leading U.S. dialysis providers, maintained DefenCath utilization through the TDAPA transition, and raised 2026 adjusted EBITDA guidance to $125-$140 million. It plans a REZZAYO prophylaxis sNDA submission in Q3 2026, with FDA action expected in H1 2027.

U.S. stock futures paused after the S&P 500 hit a record close, with softer July PPI easing near-term Fed rate-hike fears. Retail sales are set for Friday. Capricor (CAPR) surged after Cantor Fitzgerald upgraded it to Overweight and raised its target to $28. Other movers include AMAT, SNDK, WDAY, CRM, and SPCX.